Time to listen: what the experts have to say about GRAPPA and EULAR recommendations on PsA management

Episode overview

Managing psoriatic arthritis (PsA) poses a considerable challenge due to the heterogeneous disease manifestations. The European Alliance of Associations for Rheumatology (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have each published recommendations on PsA management to guide physicians in treatment decisions. What are the key differences between EULAR and GRAPPA recommendations? What questions will be addressed in the next updates with regard to treatment selections? Curious about how you can apply these recommendations in your own clinical practice? Watch these videos to find out.

The conversation is spread over four parts:

1. What are the similarities and differences between guidelines and recommendations?
2. What are the actual implications of the recommendations in the clinical practice?
3. Is there any limitation for the current recommendations?
4. How should I choose which recommendation to follow over the other ones?

Faculty

Podcast co-hosts:

Dr Alexander Egeberg
Associate professor of dermatology, and head of the psoriasis clinic at Bispebjerg Hospital in Copenhagen, Denmark

Professor Carlo Selmi
Professor and head of the Rheumatology and Clinical Immunology Unit at the Humanitas Hospital in Milan, Italy

Expert speaker:

Dr Laura Coates
Associate Professor from the Nuffield Department of Orthopaedics of the University of Oxford (Oxford, UK) and member of the Steering Committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the British Psoriatic Arthritis ConsorTium (Brit-PACT)

Part 1: What are the similarities and differences between guidelines and recommendations?

The GRAPPA recommendations and EULAR recommendations have been developed to inform clinicians about the changing therapeutic landscape and to consolidate different approaches in clinical care. Do you know the difference between guidelines and recommendations? How the decision-making processes behind GRAPPA differ from EULAR? Tune in to find out what our expert speaker has to say about how these recommendations can be applied to PsA management.

References:

McInnes IB, Behrens F, Mease PJ, et al. Lancet. 2020;395:1496-505.
Mease PJ, Smolen JS, Behrens F, et al. Ann Rheum Dis. 2020;79:123-31.
Torres T, Barcelos A, Filipe P, Fonseca JE. Front Med (Lausanne). 2021;7:618163.

Part 2: What are the actual implications of the recommendations in the clinical practice?

Do you know how much of the practice of rheumatology will be impacted by the new GRAPPA recommendations? What are the main implications, and how will GRAPPA accommodate the recent developments in available therapeutic options for PsA? Listen to our expert’s opinion about how EULAR and GRAPPA support the treat-to-target approach measuring the disease status in clinical practice.

References:

Coates LC, Helliwell PS. J Rheumatol. 2016b;43:356-61.
Gottlieb AB, Merola JF. J Am Acad Dermatol. 2021;84:92-101.
Merola JF, Ogdie A. Arthritis Rheumatol. 2019;71:1027-9.

Part 3: Is there any limitation for the current recommendations?

In this segment, our faculty discuss the remaining challenges and unmet needs that need to be addressed in the recommendations with regard to the management of psoriatic disease. Furthermore, Dr Coates also shares her thoughts on the potential of early diagnosis for PsA, the future outlooks for personalized medicine, and how this may influence the writing of treatment recommendations. Make sure you listen to it!

References:
Coates LC, Corp N, van der Windt DA, et al. J Rheumatol Suppl. 2021;97:65-6.
Gossec L, Baraliakos X, Kerschbaumer A, et al. Ann Rheum Dis. 2020;79:700-12.
Ogdie A, Coates LC, Gladman DD. Rheumatology (Oxford). 2020;59:i37-i46.

Part 4: How should I choose which recommendation to follow over the other ones?

As the number of treatment options for PsA has been growing steadily in recent years, choosing an optimal treatment for individual patients is becoming more complex. What is happening currently with new research developments, and how will these impact future treatment recommendations? Tune in to hear from Dr Coates the ongoing developments in therapeutic options and approaches for PsA, and how this could impact patient management.

References:

Lindström U, Di Giuseppe D, Delcoigne B, et al. Ann Rheum Dis. 2021;80:1410-18.
Miyagawa I, Nakayamada S, Nakano K, et al. Rheumatology (Oxford). 2019;58:336-44.
Rombach I, Tillett W, Jadon D, et al. Trials. 2021;22:185.